Kelly A Harmon1, Alyssa M Day1, Adrienne M Hammill2, Anna L Pinto3, Charles E McCulloch4, Anne M Comi5. 1. Department of Neurology, Kennedy Krieger Institute, Baltimore, Maryland. 2. Division of Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio. 3. Department of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts. 4. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California. 5. Department of Neurology, Kennedy Krieger Institute, Baltimore, Maryland; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Maryland. Electronic address: comi@kennedykrieger.org.
Abstract
AIM: We assessed the utilization of the National Institutes of Health Quality of Life in Neurological Disorders (Neuro-QoL) in pediatric patients with Sturge-Weber syndrome, a rare neurovascular disorder which frequently results in seizures, brain atrophy, calcification, and a range of neurological impairments. METHODS: Subjects were seen clinically and consented for research. All 22 patients filled out the Pediatric Neuro-QoL. The Neuro-QoL subscores were converted to T-scores to compare with the referenced control population. Twenty-one participants also filled out the Brain Vascular Malformation Consortium Database Questionnaire containing data pertaining to Sturge-Weber syndrome-related medical history, medications, comorbidities, and family history. All data were analyzed with a significance threshold of P < 0.05. RESULTS: Cognitive function quality of life was significantly lower (P < 0.001) in pediatric patients with Sturge-Weber syndrome compared with referenced control subjects. Male gender (P = 0.02) was associated with lower cognitive function Neuro-QoL. The extent of skin (R = -0.46, P = 0.04), total eyelid port-wine birthmark (R = -0.56, P = 0.007), eye (R = -0.58, P = 0.005), and total Sturge-Weber syndrome involvement (R = -0.63, P = 0.002) were negatively correlated with cognitive function Neuro-QoL. A younger age at seizure onset was associated with lower cognitive function Neuro-QoL (hazard ratio = 0.90, P = 0.004) even after controlling for extent of brain, skin, or eye involvement. Antidepressant use was associated with lower cognitive function Neuro-QoL (P = 0.005), and cognitive function Neuro-QoL was negatively correlated with depression Neuro-QoL; however, after adjusting for depression this relationship was no longer significant. CONCLUSIONS: The results suggest targeting cognitive function Neuro-QoL in treatment trials and reiterate the prognostic value of early seizure onset. In addition, sex-related differences were noted, which should be further studied.
AIM: We assessed the utilization of the National Institutes of Health Quality of Life in Neurological Disorders (Neuro-QoL) in pediatric patients with Sturge-Weber syndrome, a rare neurovascular disorder which frequently results in seizures, brain atrophy, calcification, and a range of neurological impairments. METHODS: Subjects were seen clinically and consented for research. All 22 patients filled out the Pediatric Neuro-QoL. The Neuro-QoL subscores were converted to T-scores to compare with the referenced control population. Twenty-one participants also filled out the Brain Vascular Malformation Consortium Database Questionnaire containing data pertaining to Sturge-Weber syndrome-related medical history, medications, comorbidities, and family history. All data were analyzed with a significance threshold of P < 0.05. RESULTS: Cognitive function quality of life was significantly lower (P < 0.001) in pediatric patients with Sturge-Weber syndrome compared with referenced control subjects. Male gender (P = 0.02) was associated with lower cognitive function Neuro-QoL. The extent of skin (R = -0.46, P = 0.04), total eyelid port-wine birthmark (R = -0.56, P = 0.007), eye (R = -0.58, P = 0.005), and total Sturge-Weber syndrome involvement (R = -0.63, P = 0.002) were negatively correlated with cognitive function Neuro-QoL. A younger age at seizure onset was associated with lower cognitive function Neuro-QoL (hazard ratio = 0.90, P = 0.004) even after controlling for extent of brain, skin, or eye involvement. Antidepressant use was associated with lower cognitive function Neuro-QoL (P = 0.005), and cognitive function Neuro-QoL was negatively correlated with depression Neuro-QoL; however, after adjusting for depression this relationship was no longer significant. CONCLUSIONS: The results suggest targeting cognitive function Neuro-QoL in treatment trials and reiterate the prognostic value of early seizure onset. In addition, sex-related differences were noted, which should be further studied.
Keywords:
G protein subunit alpha q; Leptomeningeal enhancement; National Institutes of Health Toolbox; Port-wine birthmark; Quality of life in neurological disorders; Sturge-Weber syndrome; Vascular malformation
Authors: Hilary Bertisch; Frederick P Rivara; Pamela A Kisala; Jin Wang; Keith Owen Yeates; Dennis Durbin; Mark R Zonfrillo; Michael J Bell; Nancy Temkin; David S Tulsky Journal: Qual Life Res Date: 2017-03-07 Impact factor: 4.147
Authors: Michael E Behen; Csaba Juhász; Cortney Wolfe-Christensen; William Guy; Stacey Halverson; Robert Rothermel; James Janisse; Harry T Chugani Journal: Epilepsy Behav Date: 2011-10 Impact factor: 2.937
Authors: Jin-Shei Lai; Cindy Nowinski; David Victorson; Rita Bode; Tracy Podrabsky; Natalie McKinney; Don Straube; Gregory L Holmes; Craig M McDonald; Erik Henricson; R Ted Abresch; Claudia S Moy; David Cella Journal: Neurorehabil Neural Repair Date: 2011-07-25 Impact factor: 3.919
Authors: Alison J Sebold; Alyssa M Day; Joshua Ewen; Jack Adamek; Anna Byars; Bernard Cohen; Eric H Kossoff; Tomoyuki Mizuno; Matthew Ryan; Jacqueline Sievers; Lindsay Smegal; Stacy J Suskauer; Cameron Thomas; Alexander Vinks; T Andrew Zabel; Adrienne M Hammill; Anne M Comi Journal: Pediatr Neurol Date: 2020-11-02 Impact factor: 3.372
Authors: Lindsay F Smegal; Alison J Sebold; Adrienne M Hammill; Csaba Juhász; Warren D Lo; Daniel K Miles; Angus A Wilfong; Alex V Levin; Brian Fisher; Karen L Ball; Anna L Pinto; Anne M Comi Journal: Pediatr Neurol Date: 2021-03-05 Impact factor: 4.210